Literature DB >> 10328138

The role of tumor necrosis factor in health and disease.

B A Beutler1.   

Abstract

The vast and growing array of cytokines is the subject of intense research for their potential to ameliorate a range of diseases that extends from autoimmune disorders to cancer and beyond. Among the cytokines, tumor necrosis factor-alpha (TNF-alpha) has proven to be a key ligand in triggering many intracellular processes, both physiological and pathological. Understanding its role in rheumatoid arthritis and Crohn's disease has produced effective new therapeutic agents, and there is reason to expect greater success as research proceeds. New synthetic macromolecules are effectively interfering with TNF and other ligands at and before the cellular membrane interface. This article reviews current knowledge of the molecular mechanics of TNF and the therapeutic inhibition of TNF action. Unraveling these processes has led to many insights into cytokine physiology and pathology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328138

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  68 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Post-transcriptional regulation of tumour necrosis factor alpha production.

Authors:  P Anderson
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

5.  Tumor necrosis factor-alpha from macrophages enhances LPS-induced clara cell expression of keratinocyte-derived chemokine.

Authors:  Arnon Elizur; Tracy L Adair-Kirk; Diane G Kelley; Gail L Griffin; Daphne E Demello; Robert M Senior
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-02       Impact factor: 6.914

6.  The role of pleural fluid-serum gradient of tumor necrosis factor-alpha concentration in discrimination between complicated and uncomplicated parapneumonic effusion.

Authors:  M Odeh; B Makhoul; E Sabo; I Srugo; A Oliven
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

Review 7.  Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.

Authors:  V Wiegering; H Morbach; A Dick; H J Girschick
Journal:  Rheumatol Int       Date:  2009-06-09       Impact factor: 2.631

8.  Tumor necrosis factor (TNF)-alpha-induced IL-8 expression in gastric epithelial cells: role of reactive oxygen species and AP endonuclease-1/redox factor (Ref)-1.

Authors:  Ann M O'Hara; Asima Bhattacharyya; Jie Bai; Randy C Mifflin; Peter B Ernst; Sankar Mitra; Sheila E Crowe
Journal:  Cytokine       Date:  2009-04-18       Impact factor: 3.861

9.  Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Xicheng Song; Peng Wei; Lei Jin; Li Chao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2013-10-24       Impact factor: 7.396

10.  TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2014-02-27       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.